Welcome to our dedicated page for Ethos Technologies news (Ticker: LIFE), a resource for investors and traders seeking the latest updates and insights on Ethos Technologies stock.
Ethos Technologies Inc. reports developments tied to its digital life insurance platform, which connects consumers, independent agents and insurance carriers through online underwriting and policy issuance tools. The company distributes life insurance products in direct-to-consumer and third-party channels and earns carrier commissions and administrator-service revenue from activated policies.
Recurring updates include quarterly results, direct and third-party channel revenue, policy activation trends, and technology integrations that expand digital purchasing. Company announcements also cover carrier collaborations and product additions, including whole life, final expense, and indexed universal life offerings delivered through Ethos' platform.
aTyr Pharma, Inc. (Nasdaq: LIFE) announced positive developments regarding efzofitimod (ATYR1923) for pulmonary sarcoidosis following a favorable End-of-Phase 2 meeting with the FDA. The company plans to initiate a registrational trial in Q3 2022.
As of December 31, 2021, aTyr's cash and investments totaled $107.9 million, supporting its R&D efforts. The FDA granted orphan drug designation for efzofitimod, offering potential market exclusivity and financial benefits. The company also announced a partnership with FUJIFILM Diosynth Biotechnologies for efzofitimod's manufacturing.
aTyr Pharma has announced a positive outcome from its Type B End-of-Phase 2 meeting with the FDA regarding its lead candidate, efzofitimod (ATYR1923), aimed at treating pulmonary sarcoidosis. The company plans to initiate a registrational study in Q3 2022, incorporating FDA feedback, including the importance of steroid-sparing effects. This follows successful data from early clinical trials demonstrating efzofitimod's safety and potential efficacy. The ongoing development reflects a significant milestone for aTyr in its commitment to providing new therapeutic options for patients.
aTyr Pharma (Nasdaq: LIFE) announced its upcoming poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, scheduled for April 8-13, 2022, in New Orleans. The poster, titled 'ATYR2810, a fully humanized monoclonal antibody targeting the VEGF-NRP2 pathway,' will focus on its potential to sensitize aggressive and chemoresistant TNBC subtypes to chemotherapy. ATYR2810 is in IND-enabling studies aimed at targeting NRP2, associated with poor outcomes in various cancers, suggesting significant therapeutic potential.
aTyr Pharma (Nasdaq: LIFE) announced it will release its Q4 and full year 2021 financial results on March 14, 2022, after the market close. The management will host a conference call and webcast at 5:00 PM EDT to discuss the results and provide a corporate update. aTyr focuses on discovering and developing innovative medicines from novel biological pathways, particularly through its product candidate efzofitimod, targeting inflammatory lung diseases.
SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, a biotherapeutics company focused on innovative medicines, will have its President and CEO, Sanjay S. Shukla, present at two investor conferences in March 2022. The first is the 34th Annual ROTH Conference from March 13-15, featuring a pre-recorded presentation. The second, the Oppenheimer 32nd Annual Healthcare Conference, is on March 16 at 4:40 PM EDT. One-on-one investor meetings will also be held. Replays of the presentations will be available on their website.
aTyr Pharma (Nasdaq: LIFE) announced its participation in the NIH Rare Disease Day virtual conference on February 28, 2022, at 2:55pm EST. Sanjay S. Shukla, M.D., CEO, will join a panel discussing strategies for clinical trial recruitment, emphasizing lessons learned from the Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis during the pandemic. The event features industry leaders advocating for rare diseases awareness. aTyr is currently developing efzofitimod for severe inflammatory lung diseases, with a registrational trial expected to start this year.
aTyr Pharma (Nasdaq: LIFE) announced that its President and CEO, Sanjay S. Shukla, will present a corporate overview at the BIO CEO & Investor Conference from February 14 to 17, 2022, at the Marriott Marquis, New York.
The presentation is scheduled for February 15, 2022, at 1:15 p.m. EST. Additionally, aTyr management will engage in both in-person and virtual one-on-one meetings during the conference. More information about aTyr's innovative biotherapeutics focusing on tRNA synthetases can be found at www.atyrpharma.com.
aTyr Pharma has announced the nonproprietary name efzofitimod for its drug ATYR1923, which is under clinical development for pulmonary sarcoidosis. The company aims to initiate a registrational trial in 2022. Efzofitimod, an immunomodulator targeting neuropilin-2, is engineered from a splice variant of histidyl-tRNA synthetase and is viewed as a potential treatment for severe inflammatory lung diseases. Initial Phase 1b/2a clinical trials showed promising safety and efficacy, including improvements in lung function and reduced steroid use.
aTyr Pharma (Nasdaq: LIFE) announced that the FDA granted orphan drug designation for its candidate ATYR1923, aimed at treating pulmonary sarcoidosis, a chronic inflammatory disease affecting nearly 200,000 patients in the U.S. This milestone is significant as ATYR1923 may offer a transformative alternative to current treatments that are often limited and come with severe side effects. The company expects to begin a registrational trial this year after establishing clinical proof-of-concept in a recent Phase 1b/2a study.
aTyr Pharma (Nasdaq: LIFE), a company focused on innovative biotherapeutics, announced that Jill Broadfoot, Chief Financial Officer, will present a corporate overview at the H.C. Wainwright Virtual BioConnect Conference from January 10-13, 2022. The presentation will be available on-demand for registered attendees starting January 10, 2022, at 7:00 am ET, and can also be accessed on the company’s website for 90 days post-event. aTyr’s primary product candidate, ATYR1923, targets inflammatory lung diseases.